First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia
FELDMAN, Eric J, LANCET, Jeffrey E, LOUIE, Arthur C, KOLITZ, Jonathan E, RITCHIE, Ellen K, ROBOZ, Gail J, LIST, Alan F, ALLEN, Steven L, ASATIANI, Ekatherine, MAYER, Lawrence D, SWENSON, Christine
Published in Journal of clinical oncology (10.03.2011)
Published in Journal of clinical oncology (10.03.2011)
Get full text
Journal Article
Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors
BATIST, Gerald, GELMON, Karen A, CHI, Kim N, MILLER, Wilson H, CHIA, Stephen K. L, MAYER, Lawrence D, SWENSON, Christine E, JANOFF, Andrew S, LOUIE, Arthur C
Published in Clinical cancer research (15.01.2009)
Published in Clinical cancer research (15.01.2009)
Get full text
Journal Article
Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm
Walter, Roland B, Othus, Megan, Orlowski, Kaysey F, McDaniel, Emily N, Scott, Bart L, Becker, Pamela S, Percival, Mary-Elizabeth M, Hendrie, Paul C, Medeiros, Bruno C, Chiarella, Michael T, Louie, Arthur C, Estey, Elihu H
Published in Haematologica (Roma) (01.03.2018)
Published in Haematologica (Roma) (01.03.2018)
Get full text
Journal Article
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia
Lancet, Jeffrey E, Uy, Geoffrey L, Cortes, Jorge E, Newell, Laura F, Lin, Tara L, Ritchie, Ellen K, Stuart, Robert K, Strickland, Stephen A, Hogge, Donna, Solomon, Scott R, Stone, Richard M, Bixby, Dale L, Kolitz, Jonathan E, Schiller, Gary J, Wieduwilt, Matthew J, Ryan, Daniel H, Hoering, Antje, Banerjee, Kamalika, Chiarella, Michael, Louie, Arthur C, Medeiros, Bruno C
Published in Journal of clinical oncology (10.09.2018)
Published in Journal of clinical oncology (10.09.2018)
Get full text
Journal Article
Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML
Lancet, Jeffrey E., Cortes, Jorge E., Hogge, Donna E., Tallman, Martin S., Kovacsovics, Tibor J., Damon, Lloyd E., Komrokji, Rami, Solomon, Scott R., Kolitz, Jonathan E., Cooper, Maureen, Yeager, Andrew M., Louie, Arthur C., Feldman, Eric J.
Published in Blood (22.05.2014)
Published in Blood (22.05.2014)
Get full text
Journal Article
Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML
Cortes, Jorge E, Goldberg, Stuart L, Feldman, Eric J, Rizzeri, David A, Hogge, Donna E, Larson, Melissa, Pigneux, Arnaud, Recher, Christian, Schiller, Gary, Warzocha, Krzysztof, Kantarjian, Hagop, Louie, Arthur C, Kolitz, Jonathan E
Published in Cancer (15.01.2015)
Published in Cancer (15.01.2015)
Get full text
Journal Article
Health state utilities associated with treatment options for acute myeloid leukemia (AML)
Matza, Louis S, Deger, Kristen A, Howell, Timothy A, Koetter, Kimberly, Yeager, Andrew M, Hogge, Donna, Fisher, Vicki, Louie, Arthur C, Chung, Karen C
Published in Journal of medical economics (03.06.2019)
Published in Journal of medical economics (03.06.2019)
Get more information
Journal Article
Study Design of an Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients 60-75 Years of Age with Secondary Acute Myeloid Leukemia
Larson, Melissa L, Rubenstein, S. Eric, Schiller, Gary J, Solomon, Scott R, Louie, Arthur C, Paulsen, Kim H, Lin, Tara L
Published in Biology of blood and marrow transplantation (01.03.2017)
Published in Biology of blood and marrow transplantation (01.03.2017)
Get full text
Journal Article
Analysis of Transplantation Rate and Overall Treatment Efficacy by Age for Patients Aged 60 to 75 with Untreated Secondary Acute Myeloid Leukemia (AML) Given CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial
Lancet, Jeffery, Uy, Geoffrey L, Cortes, Jorge, Newell, Laura F, Lin, Tara L, Ritchie, Ellen, Stuart, Robert, Strickland, Stephen, Hogge, Donna, Solomon, Scott R, Stone, Richard M, Bixby, Dale L, Kolitz, Jonathan E, Schiller, Gary J, Wieduwilt, Matthew J, Ryan, Daniel H, Hoering, Antje, Chiarella, Michael, Louie, Arthur C, Medeiros, Bruno C
Published in Biology of blood and marrow transplantation (01.03.2017)
Published in Biology of blood and marrow transplantation (01.03.2017)
Get full text
Journal Article
Enhanced Cytarabine and Daunorubicin Population Pharmacokinetics When Administered As CPX-351: A Novel Liposomal Formulation Not Requiring Dose Reduction for Mild Renal or Hepatic Dysfunction
Nikanjam, Mina, Capparelli, Edmund, Lancet, Jeffrey E., Kolitz, Jonathan E., Louie, Arthur C., Schiller, Gary J.
Published in Blood (02.12.2016)
Published in Blood (02.12.2016)
Get full text
Journal Article
Burden of Acute Myeloid Leukemia (AML) Among Older Newly-Diagnosed Patients
Sacks, Naomi C., Cyr, Phil, Liu, Yanmei, Miller, Derek J., Chiarella, Michael T., Louie, Arthur C.
Published in Blood (02.12.2016)
Published in Blood (02.12.2016)
Get full text
Journal Article
Cost-Effectiveness of CPX-351 Versus 7+3 Regimen in the Treatment of Treatment-Related Acute Myeloid Leukemia (tAML) or AML with Myelodysplasia-Related Changes (MRC)
Kansal, Anuraag, Du, Mark, Herrera-Restrepo, Oscar, Leipold, Robert, Ryan, Robert J., Louie, Arthur C., Chung, Karen
Published in Blood (08.12.2017)
Published in Blood (08.12.2017)
Get full text
Journal Article
Final Safety and Efficacy Results from the CPX-351 Early Access Program (EAP) for Older Patients with High-Risk/Secondary Acute Myeloid Leukemia (sAML)
Roboz, Gail J., Larson, Melissa L., Rubenstein, S. Eric, Solomon, Scott R, Schiller, Gary J., An, Qi, Mancino, Emaryn, Chiarella, Michael, Louie, Arthur C., Lin, Tara L
Published in Blood (29.11.2018)
Published in Blood (29.11.2018)
Get full text
Journal Article
CPX-351 Enables Administration of Consolidation Treatment in the Outpatient Setting and Increases the Time Spent out of the Hospital after Completion of AML Treatment Compared with 7+3
Lancet, Jeffrey E, Cyr, Phillip, Sacks, Naomi, Chiarella, Michael T., Louie, Arthur C., Cortes, Jorge E.
Published in Blood (03.12.2015)
Published in Blood (03.12.2015)
Get full text
Journal Article
Randomized Study of CPX-351 for Medically Less-Fit Adults with Newly Diagnosed Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasm
Walter, Roland B., Othus, Megan, Orlowski, Kaysey F., McDaniel, Emily N., Scott, Bart L., Becker, Pamela S., Percival, Mary-Elizabeth M., Hendrie, Paul C., Medeiros, Bruno C, Chiarella, Michael T., Louie, Arthur C., Estey, Elihu H.
Published in Blood (08.12.2017)
Published in Blood (08.12.2017)
Get full text
Journal Article
The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML
Lin, Tara L, Cortes, Jorge E., Newell, Laura F., Ritchie, Ellen K., Stuart, Robert K., Strickland, Stephen A., Hogge, Donna, Solomon, Scott R, Stone, Richard M., Bixby, Dale L., Kolitz, Jonathan E., Schiller, Gary J., Wieduwilt, Matthew J., Ryan, Daniel H., Ryan, Robert, Chiarella, Michael, Louie, Arthur C., Uy, Geoffrey L.
Published in Blood (29.11.2018)
Published in Blood (29.11.2018)
Get full text
Journal Article
Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study
Ryan, Daniel H., Uy, Geoffrey L., Cortes, Jorge E., Newell, Laura F., Ritchie, Ellen K., Stuart, Robert K., Strickland, Stephen A., Hogge, Donna, Solomon, Scott R, Stone, Richard M., Bixby, Dale L., Kolitz, Jonathan E., Schiller, Gary J., Wieduwilt, Matthew J., Ryan, Robert, Chiarella, Michael, Louie, Arthur C., Lancet, Jeffrey E.
Published in Blood (29.11.2018)
Published in Blood (29.11.2018)
Get full text
Journal Article
CPX-351 ((Cytarabine:Daunorubicin) Liposome Injection, (Vyxeos)) Does Not Prolong Qtcf Intervals, Requires No Dose Adjustment for Impaired Renal Function and Induces High Rates of Complete Remission in Acute Myeloid Leukemia
Lin, Tara L., Newell, Laura F., Stuart, Robert K., Michaelis, Laura C., Rubenstein, Stephen E., Pentikis, Helen S., Callahan, Timothy, Alvarez, Donna, Mayer, Lawrence D., Louie, Arthur C.
Published in Blood (03.12.2015)
Published in Blood (03.12.2015)
Get full text
Journal Article